GSK3-beta activation is a key driver of resistance to RAF inhibition in BRAF mutant melanoma cells

被引：0
|
作者：
Crisan, D. [1 ]
Scharffetter-Kochanek, K. [1 ]
Zhao, F. [2 ]
Paschen, A. [2 ]
Schatz, S. [1 ]
Hainzl, H. [1 ]
Baican, A. [3 ]
Crisan, M. [3 ]
Basu, A. [1 ]
Sindrilaru, A. [1 ]
机构：
[1] Univ Hosp Ulm, Clin Dermatol & Allerg Dis, D-89081 Ulm, Germany
[2] Univ Hosp Essen, Dermatol Clin, Essen, Germany
[3] Univ Clin Cluj Napoca, Clin Dermatol & Venerol, Cluj Napoca, Romania
来源：
EXPERIMENTAL DERMATOLOGY | 2023年 / 32卷 / 04期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
P058
引用
收藏
页码：E30 / E30
页数：1
相关论文
共 50 条
  • [31] Cyclic AMP/PKA signaling activates canonical Wnt pathway via phosphorylation of GSK3-Beta in osteoblastic cells.
    Suzuki, A.
    Ozono, K.
    Kubota, T.
    Michigami, T.
    JOURNAL OF BONE AND MINERAL RESEARCH, 2006, 21 : S260 - S260
  • [32] Resistance to BRAF Inhibition in BRAF-Mutant Colon Cancer Can Be Overcome with PI3K Inhibition or Demethylating Agents
    Mao, Muling
    Tian, Feng
    Mariadason, John M.
    Tsao, Chun C.
    Lemos, Robert, Jr.
    Dayyani, Farshid
    Gopal, Y. N. Vashisht
    Jiang, Zhi-Qin
    Wistuba, Ignacio I.
    Tang, Xi M.
    Bornman, William G.
    Bollag, Gideon
    Mills, Gordon B.
    Powis, Garth
    Desai, Jayesh
    Gallick, Gary E.
    Davies, Michael A.
    Kopetz, Scott
    CLINICAL CANCER RESEARCH, 2013, 19 (03) : 657 - 667
  • [33] Morphological architectures of patient-derived hepatocellular carcinoma organoids with GSK3-beta expression dependent variability according to lenvatinib resistance
    Cho, Kyung Joo
    Park, Jun Yong
    Lee, Hye Won
    Park, Hye Jung
    Lee, Eun Kong
    Seo, Sang Hyun
    Lee, Jae Seung
    Kim, Beom Kyung
    Kim, Seung Up
    Kim, Do Young
    Ahn, Sang Hoon
    JOURNAL OF HEPATOLOGY, 2023, 78 : S552 - S553
  • [34] BRAF inhibition promotes BRAF mutant human melanoma cell survival under nutrient-deprived conditions through activation of mitochondrial metabolism
    Delgado-Goni, T.
    Wantuch, S.
    Workman, P.
    Marais, R.
    Leach, M. O.
    Beloueche-Babari, M.
    EUROPEAN JOURNAL OF CANCER, 2016, 61 : S104 - S104
  • [35] Low inducible expression of p21Cip1 confers resistance to paclitaxel in BRAF mutant melanoma cells with acquired resistance to BRAF inhibitor
    Jang, Gun-Hee
    Kim, Na-Yeon
    Lee, Michael
    MOLECULAR AND CELLULAR BIOCHEMISTRY, 2015, 406 (1-2) : 53 - 62
  • [36] Low inducible expression of p21Cip1 confers resistance to paclitaxel in BRAF mutant melanoma cells with acquired resistance to BRAF inhibitor
    Gun-Hee Jang
    Na-Yeon Kim
    Michael Lee
    Molecular and Cellular Biochemistry, 2015, 406 : 53 - 62
  • [37] Sensitivity of Melanoma Cells to EGFR and FGFR Activation but Not Inhibition is Influenced by Oncogenic BRAF and NRAS Mutations
    Garay, Tamas
    Molnar, Eszter
    Juhasz, Eva
    Laszlo, Vikoria
    Barbai, Tamas
    Dobos, Judit
    Schelch, Karin
    Pirker, Christine
    Grusch, Michael
    Berger, Walter
    Timar, Jozsef
    Hegedus, Balazs
    PATHOLOGY & ONCOLOGY RESEARCH, 2015, 21 (04) : 957 - 968
  • [38] EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition by vemurafenib
    Corcoran, Ryan B.
    Ebi, Hiromichi
    Turke, Alexa B.
    Coffee, Erin M.
    Nishino, Michiya
    Cogdill, Alexandra P.
    Brown, Ronald D.
    Dias-Santagata, Dora
    Della Pelle, Patricia
    Hung, Kenneth E.
    Flaherty, Keith T.
    Piris, Adriano
    Wargo, Jennifer A.
    Settleman, Jeffrey
    Mino-Kenudson, Mari
    Engelman, Jeffrey A.
    CANCER RESEARCH, 2012, 72
  • [39] Combination of MEK and PI3K inhibition in BRAF wild-type and mutant melanoma
    Zhang, Yanping
    Peng, Guangyong
    Hsueh, Eddy C.
    CANCER RESEARCH, 2016, 76
  • [40] MK-2206 EFFECTIVELY TARGET LEUKEMIA CELLS VIA GSK3-BETA MEDIATED MCL-1 MODULATION
    Lin, Y. M.
    Lai, Y. L.
    Hu, C. Y.
    Chen, C. Y.
    Ou, D. L.
    Tien, H. F.
    Lin, L. I.
    HAEMATOLOGICA, 2012, 97 : 16 - 17
12345